Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known as eczema.
Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a deal ...
Tentokrát přinášíme rozhovor s Ilyasem Zivanou, kulturním manažerem institutu pro zahraniční vztahy, který je činný ve Shromáždění německých spolků v České republice. Ptali jsme se ho, co má na ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback